ADC Therapeutics ADCT
NYSE ADCT
$1.00 +0.04 (+3.80%)
At close: Aug 21, 2026 · 4:00 PM EDT

ADC Therapeutics (ADCT) Cost of Revenue (2021 - 2026)

ADC Therapeutics (ADCT) posted Cost of Revenue of $3.5 million for Q1 2026, up 188.44% sequentially from $1.2 million in Q3 2025, and up 68.22% YoY from $2.1 million in Q1 2025.

ADC Therapeutics (ADCT) Cost of Revenue (2021 - 2026) Analysis & Trends

ADC Therapeutics has reported Cost of Revenue for 6 years, with the latest figure at $3.5 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 489.20 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 360.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 145.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 93.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 174.53 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 298.26 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 387.98 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 67.21 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 ADC Therapeutics 154.55 Mn -64.56 Mn 17.14 Mn 2.10 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 2.10 Mn
Jun 30, 2026 2.10 Mn
Mar 31, 2026 3.47 Mn
Mar 31, 2026 3.47 Mn
Sep 30, 2025 1.20 Mn
Sep 30, 2025 1.20 Mn
Jun 30, 2025 836,000.00
Jun 30, 2025 836,000.00
Mar 31, 2025 2.06 Mn
Mar 31, 2025 2.06 Mn
Sep 30, 2024 851,000.00
Sep 30, 2024 851,000.00
Jun 30, 2024 1.22 Mn
Jun 30, 2024 1.22 Mn
Mar 31, 2024 2.51 Mn
Mar 31, 2024 2.51 Mn
Sep 30, 2023 366,000.00
Sep 30, 2023 366,000.00
Jun 30, 2023 1.32 Mn
Jun 30, 2023 1.32 Mn